Kyorin University   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Tokoyo Japan (1970)

Organization Overview

First Clinical Trial
2007
NCT00541853
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Kyorin University Faculty of Medicine, Department of Neurosurgery | Kyorin University School of Medicine | Kyorin University, School of Medicine

Active Ingredients

Drugs in Phase 4 Trials (4)

bevacizumab (avastin) (2 trials)

candesartan (atacand) (1 trial)

frc-8653 (1 trial)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 3 Trials (1)

temozolomide (temodar) (1 trial)

Drugs in Other Trials (2)

alteplase (Activase) (1 trial)

tolvaptan (samsca) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 4)

Glioblastoma (Phase 3)

Macular Edema (Phase 4)

Polycystic Kidney, Autosomal Dominant (Phase 4)

Polycystic Kidney Diseases (Phase 4)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7